» Articles » PMID: 36630532

Impact of Nanoparticles on Amyloid β-induced Alzheimer's Disease, Tuberculosis, Leprosy and Cancer: a Systematic Review

Overview
Journal Biosci Rep
Specialty Cell Biology
Date 2023 Jan 11
PMID 36630532
Authors
Affiliations
Soon will be listed here.
Abstract

Nanotechnology is an interdisciplinary domain of science, technology and engineering that deals with nano-sized materials/particles. Usually, the size of nanoparticles lies between 1 and 100 nm. Due to their small size and large surface area-to-volume ratio, nanoparticles exhibit high reactivity, greater stability and adsorption capacity. These important physicochemical properties attract scientific community to utilize them in biomedical field. Various types of nanoparticles (inorganic and organic) have broad applications in medical field ranging from imaging to gene therapy. These are also effective drug carriers. In recent times, nanoparticles are utilized to circumvent different treatment limitations. For example, the ability of nanoparticles to cross the blood-brain barrier and having a certain degree of specificity towards amyloid deposits makes themselves important candidates for the treatment of Alzheimer's disease. Furthermore, nanotechnology has been used extensively to overcome several pertinent issues like drug-resistance phenomenon, side effects of conventional drugs and targeted drug delivery issue in leprosy, tuberculosis and cancer. Thus, in this review, the application of different nanoparticles for the treatment of these four important diseases (Alzheimer's disease, tuberculosis, leprosy and cancer) as well as for the effective delivery of drugs used in these diseases has been presented systematically. Although nanoformulations have many advantages over traditional therapeutics for treating these diseases, nanotoxicity is a major concern that has been discussed subsequently. Lastly, we have presented the promising future prospective of nanoparticles as alternative therapeutics. In that section, we have discussed about the futuristic approach(es) that could provide promising candidate(s) for the treatment of these four diseases.

Citing Articles

Therapeutic Potential of Arimoclomol Nanomicelles: In Vitro Impact on Alzheimer's and Parkinson's Pathology and Correlation with In Vivo Inflammatory Response.

Xavier-de-Britto I, Gomes-da-Silva N, Gomes Soares M, Follmer C, Dabkiewicz D, Rebelo Alencar L ACS Chem Neurosci. 2025; 16(4):699-710.

PMID: 39907698 PMC: 11843614. DOI: 10.1021/acschemneuro.4c00734.


Leprosy: Comprehensive insights into pathology, immunology, and cutting-edge treatment strategies, integrating nanoparticles and ethnomedicinal plants.

Kimta N, Majdalawieh A, Nasrallah G, Puri S, Nepovimova E, Jomova K Front Pharmacol. 2024; 15:1361641.

PMID: 38818380 PMC: 11137175. DOI: 10.3389/fphar.2024.1361641.


Polymeric nanoparticles: A promising strategy for treatment of Alzheimer's disease.

Elmahboub Y, Elkordy A J Taibah Univ Med Sci. 2024; 19(3):549-565.

PMID: 38736898 PMC: 11087974. DOI: 10.1016/j.jtumed.2024.04.004.


Silver nanoparticles alter the dimerization of Aβ studied by REMD simulations.

Thai Q, Tran P, Phung H, Pham M, Ngo S RSC Adv. 2024; 14(21):15112-15119.

PMID: 38720971 PMC: 11078207. DOI: 10.1039/d4ra02197e.


Recent Developments of Hybrid Fluorescence Techniques: Advances in Amyloid Detection Methods.

Prasanna A, Sen P Curr Protein Pept Sci. 2024; 25(9):667-681.

PMID: 38715332 DOI: 10.2174/0113892037291597240429094515.


References
1.
Bastus N, Comenge J, Puntes V . Kinetically controlled seeded growth synthesis of citrate-stabilized gold nanoparticles of up to 200 nm: size focusing versus Ostwald ripening. Langmuir. 2011; 27(17):11098-105. DOI: 10.1021/la201938u. View

2.
de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

3.
Monteiro L, Lione V, do Carmo F, do Amaral L, da Silva J, Nasciutti L . Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int J Nanomedicine. 2012; 7:5175-82. PMC: 3463397. DOI: 10.2147/IJN.S36479. View

4.
Abbas M . Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients. Polymers (Basel). 2021; 13(7). PMC: 8036916. DOI: 10.3390/polym13071051. View

5.
Audisio D, Messaoudi S, Cegielkowski L, Peyrat J, Brion J, Methy-Gonnot D . Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery. ChemMedChem. 2011; 6(5):804-15. DOI: 10.1002/cmdc.201000489. View